BioNTech Results Presentation Deck

Highlights in Q2: COVID-19 Vaccine / COMIRNATY 9 Broad label across age groups Strong global distribution da Variant adapted & next-gen vaccines ● FDA granted EUA for primary series in children 6 months through 4 yrs of age and for booster dose in children 5 through 11 yrs of age Pediatric label now includes ¹: 6 mo. to <5 yrs (3 µg) 5 yrs to <12 yrs (10 µg) 12 yrs + (30 µg) ● ● ● More than 3.6 bn doses delivered to 180 countries and territories since launch Dec. 2020² Order book 2022: ~2.5 bn doses² New agreement with U.S. government to provide additional 105m doses of COVID-19 vaccine with option for another 195m doses Fostering global health equity: On track to deliver a total of 2 bn doses to low- and middle-income countries by end of 2022 ● Variant adapted vaccines: Omicron BA.1 adapted vaccine candidates demonstrated high immunogenicity and tolerable safety profile Regulatory submissions of Omicron BA.1- and BA.4/5-adapted bivalent vaccines are ongoing worldwide Next-gen vaccines: ● ● ● Initiated Phase 2 trial of BNT162b5: bivalent vaccine candidate based on enhanced versions of SARS-CoV-2 ancestral strain and Omicron BA.2 variant spike proteins engineered for broader immunity 1 Approved as a 2-dose series for prevention of COVID-19 in individuals 12 yrs of age and older; 2-dose series under Emergency Use Authorization for individuals 5-11 yrs old, and 3-dose series under emergency use authorization for children 6 months through 4 yrs of age 2 As of beginning of July 2022 BIONTECH

View entire presentation